We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Two new quality standards, one for MDMA and another for psilocybine, have been published. These standards each specify the minimum quality requirements for both the active pharmaceutical ingredient (API) and finished product.
Commencement
The quality standards have been registered as Therapeutic Goods Orders (TGOs) on the Federal Register of Legislation:
- Therapeutic Goods (Standard for MDMA) Order 2024 (TGO 112)
- Therapeutic Goods (Standard for psilocybine) Order 2024 (TGO 113).
From 6 January 2025, all MDMA and psilocybine API and finished products supplied or manufactured in Australia must comply with the relevant TGO.
Guidance material
We will publish guidance material to help manufacturers and sponsors understand how these TGOs set the minimum quality requirements that must be met for these medicines.
